Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matti Waterman

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Clinics and Research in Hepatology and Gastroenterology|May 22, 2019
Thiopurine hepatotoxicity can mimic intrahepatic cholestasis of pregnancyRoni Nasser, Daniel Kurnik, Yael Lurie, et al.
Nutrients|September 27, 2025
Understanding Patient and Physician Perspectives on Exclusive Enteral Nutrition in Adults with Crohn's Disease: Bridging the Gap in Nutritional TherapyRamit Magen-Rimon, David Mamet, Meis Assaf, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 30, 2012
Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel diseaseShomron Ben-Horin, Matti Waterman, Uri Kopylov, et al.
Inflammatory Bowel Diseases|April 28, 2016
Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel AssayRoni Weisshof, Bella Ungar, Alexandra Blatt, et al.
Digestive Diseases and Sciences|October 11, 2022
Trends in Biochemical Parameters, Healthcare Resource and Medication Use in the 5 Years Preceding IBD Diagnosis: A Health Maintenance Organization Cohort StudyNathaniel A Cohen, Efrat Kliper, Noa Zamstein, et al.
The American Journal of Gastroenterology|May 19, 2007
Risk factors for perianal Crohn's disease: the role of genotype, phenotype, and ethnicityAmir Karban, Maza Itay, Ofir Davidovich, et al.
Journal of Crohn'S & Colitis|December 1, 2021
Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease PatientsHaggai Bar-Yoseph, Alexandra Blatt, Shiran Gerassy, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of ThiopurinesHaggai Bar-Yoseph, Matti Waterman, Ronit Almog, et al.
Inflammatory Bowel Diseases|May 15, 2013
Thiopurine effectiveness in patients with Crohn's disease: a study of genetic and clinical predictive factorsEduard Koifman, Amir Karban, Yoav Mazor, et al.
Journal of Pediatric Gastroenterology and Nutrition|July 9, 2015
Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto GroupLissy de Ridder, Matti Waterman, Dan Turner, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Clinics and Research in Hepatology and Gastroenterology|May 22, 2019
Thiopurine hepatotoxicity can mimic intrahepatic cholestasis of pregnancyRoni Nasser, Daniel Kurnik, Yael Lurie, et al.
Nutrients|September 27, 2025
Understanding Patient and Physician Perspectives on Exclusive Enteral Nutrition in Adults with Crohn's Disease: Bridging the Gap in Nutritional TherapyRamit Magen-Rimon, David Mamet, Meis Assaf, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 30, 2012
Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel diseaseShomron Ben-Horin, Matti Waterman, Uri Kopylov, et al.
Inflammatory Bowel Diseases|April 28, 2016
Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel AssayRoni Weisshof, Bella Ungar, Alexandra Blatt, et al.
Digestive Diseases and Sciences|October 11, 2022
Trends in Biochemical Parameters, Healthcare Resource and Medication Use in the 5 Years Preceding IBD Diagnosis: A Health Maintenance Organization Cohort StudyNathaniel A Cohen, Efrat Kliper, Noa Zamstein, et al.
The American Journal of Gastroenterology|May 19, 2007
Risk factors for perianal Crohn's disease: the role of genotype, phenotype, and ethnicityAmir Karban, Maza Itay, Ofir Davidovich, et al.
Journal of Crohn'S & Colitis|December 1, 2021
Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease PatientsHaggai Bar-Yoseph, Alexandra Blatt, Shiran Gerassy, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of ThiopurinesHaggai Bar-Yoseph, Matti Waterman, Ronit Almog, et al.
Inflammatory Bowel Diseases|May 15, 2013
Thiopurine effectiveness in patients with Crohn's disease: a study of genetic and clinical predictive factorsEduard Koifman, Amir Karban, Yoav Mazor, et al.
Journal of Pediatric Gastroenterology and Nutrition|July 9, 2015
Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto GroupLissy de Ridder, Matti Waterman, Dan Turner, et al.
Pageof 5